After being reviewed and approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University (Ethics Review No. YW2018 - 018 - 01/02/03), the clinical trial titled "A Randomized, Controlled, Open - Label, Multi - center, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of CHA for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM)", presided over by Professor Li Wenbin, Director of the Comprehensive Treatment Ward for Neuro - Oncology in the Department of Neurosurgery of Beijing Tiantan Hospital, has been officially launched. After the Spring Festival in 2019, recruitment of recurrent glioblastoma patients who meet the inclusion criteria will officially start from the general public.

The "3rd China Pharmaceutical Innovation and Investment Conference" was held at the Conference Center of Suzhou Bio-industry Park on September 18, 2018. At the conference, Jiuzhang Biotech delivered a special report titled "Review of Phase I Clinical Data of CHA for Injection, a Natural Small-Molecule Innovative Drug for Glioma Treatment, and Prospects for Phase II Clinical Trials".

On May 19, 2018, the "Discussion Meeting on the Clinical Trial Protocol for CHA for Injection in the Treatment of GBM Phase II/III" organized by our company (the sponsor) came to a successful conclusion.

On April 1, 2018, a discussion meeting on the protocol of a single-arm, open-label, multi-center Phase Ib/IIa clinical study of CHA for injection in the treatment of advanced lung cancer was held at Guangxi Building in Beijing.

All the subjects participating in the Phase I clinical trial of CHA for injection were patients with high - grade malignant gliomas who had failed international standard treatments such as surgery, radiotherapy and chemotherapy. The results of the Phase I clinical trial prove that CHA injection is safe with extremely low toxic and side effects. Its pharmacokinetic pathway is clear and there is no cumulative toxicity. The treatment effect exceeds the researchers' expectations. For recurrent patients who have failed the classic treatment methods, after using CHA for injection, their median overall survival time is at least 2 to 5 times longer than the globally recognized one.

The "2nd China Pharmaceutical Innovation and Investment Conference" was held at the Suzhou Jinji Lake International Convention Center on October 29, 2017. Jiuzhang Biotech released the Phase I clinical trial data on the safety, tolerability and pharmacokinetics of CHA for injection in the treatment of advanced malignant gliomas.